Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
Lilly reports 52-week results of Taltz and Zepbound in psoriatic arthritis and obesity
The company said that at one year 43.7% of patients receiving Taltz and Zepbound achieved ACR50 compared with 15.7% for Taltz alone. The 52-week Phase 3b study randomized 271 participants 1:1 to the combination or Taltz monotherapy and reported mild to moderate adverse events consistent with each drug's known safety profile.
-
Amgen announces positive Phase 3 results for dazodalibep in Sjögren's disease
Amgen said the Phase 3 OASIZ-301 study met its primary endpoint, with both 1,500 mg every four weeks and 3,000 mg every 12 weeks regimens showing statistically significant reductions in ESSDAI score versus placebo at Week 48. The company noted improvements in patient-reported dryness and that the most common adverse events were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions.
-
Xtalks hosts webinar on using EHR and applied AI to speed patient recruitment
The webinar, scheduled for Wednesday, December 2, 2026 at 10am EST, explores how integrating EHR capabilities with applied AI can improve patient identification and reduce manual record review. Speakers include Mike Margiotta of AiSync, Meagan Garvin of Trialbee, and Carl Wolff of Trialbee.
-
NEB and Mammoth Biosciences launch MB-CasFire enzyme for one-pot isothermal assays
NEB will manufacture and globally distribute Mammoth Biosciences' proprietary MB-CasFire enzyme, a thermostable Type V CRISPR nuclease that works across 37-65 °C and can be coupled directly with LAMP, RPA and NEAR assays. MB-CasFire resolves targets at single-nucleotide resolution and simplifies assay architecture by eliminating the need for multiple temperature incubations or component additions.
-
ISTx registers Phase 3 trial of ceftobiprole in pediatric Staphylococcus aureus bacteremia
The study, led by ISTx, LLC, plans to enroll 60 participants and begin on October 30, 2026, to compare ceftobiprole with standard-of-care antibiotics in children under 18 with Staphylococcus aureus bacteremia, including right-sided infective endocarditis. The trial will also evaluate safety, tolerability, efficacy, and pharmacokinetics of ceftobiprole.
-
Phase 3 results posted, week of November 9, 2026: 11 industry trials
Industry sponsors posted results for 11 Phase 3 trials on ClinicalTrials.gov in the week of November 9 to 15, 2026. Together the trials enrolled 3,269 participants; the largest, Janssen Research & Development's Seltorexant trial, enrolled 757.
-
Sanofi registers Phase 3 trial of venglustat vs Cerezyme in pediatric Gaucher disease type 3
The study, titled LEAP2KIDS, plans to enroll 18 pediatric participants aged 2 to 11 years with Gaucher Disease Type III who have reached therapeutic goals with enzyme replacement therapy. It is a randomized, open-label, active-comparator trial with a 52-week primary analysis period and a 52-week extended treatment period.
-
Boehringer Ingelheim registers Phase 3 safety rollover trial of obrixtamig in advanced cancer
The study, first posted on ClinicalTrials.gov on November 10, 2026, plans to enroll 68 participants and begin in March 2027. It plans to find out how well participants who received obrixtamig in a previous study tolerate the drug.
-
Apellis posts results of Pegcetacoplan long-term safety extension study
The study, completed on September 4, 2025, enrolled 137 participants who had previously completed a pegcetacoplan study. It was an open-label, non-randomized, multi-center Phase 3 extension study evaluating long-term safety and efficacy in PNH.
-
Alcon posts results of Phase 3 FID 123320 study
The study enrolled 284 participants and was completed with results first posted on ClinicalTrials.gov on November 10, 2026. It assessed the safety and efficacy of FID 123320 Ophthalmic Solution (Apraclonidine HCl 0.125%) versus vehicle for relieving ocular redness in pediatric and adult populations.
-
Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL in China
Results for the study were first posted on ClinicalTrials.gov on November 10, 2026. The trial enrolled 72 participants who were randomized to receive epcoritamab or investigator's choice chemotherapy for relapsed/refractory diffuse large B-cell lymphoma.
-
Alcon posts results of Phase 3 apraclonidine study for ocular redness
The study enrolled 159 participants and was completed on November 14, 2024. Results were first posted on ClinicalTrials.gov on November 10, 2026.